Zinger Key Points
- Aclarion secured $20 million in funding for its clinical trial of Nociscan.
- Nociscan is a diagnostic tool that aims to improve surgical outcomes for chronic low back pain patients.
Aclarion, Inc. ACON stock is trading higher on Tuesday after the company announced it secured funding for its CLARITY trial of its diagnostic tool, Nociscan.
What To Know: The company has raised approximately $20 million in gross proceeds since the start of 2025, which will fully fund the clinical trial. The trial aims to test Nociscan's ability to improve surgical outcomes for chronic low back pain patients.
The trial will enroll 300 patients across multiple sites and build on peer-reviewed data, demonstrating Nociscan's ability to improve surgical outcomes by helping surgeons target the specific discs identified by the tool as the source of pain.
Chief Strategy Officer Ryan Bond stated, “This milestone ensures we reach the study’s conclusion, potentially unlocking broad payer coverage and redefining chronic low back pain treatment.”
Related Link: Behind the Scenes of Meta Platforms’s Latest Options Trends
ACON Price Action: At the time of writing, Aclarion shares are trading 6.02% higher at $7.05, according to data from Benzinga Pro.
Image: via Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
